Humans are exposed to complex mixtures of polycyclic aromatic hydrocarbons in the atmosphere. We examined the long term effects of a standard reference material (SRM) 1649a over time on the metabolic activation and DNA adduct formation by two carcinogenic PAH, benzoyrene (BP) and dibenzo [a,l] 
INTRODUCTION
Humans can be environmentally exposed to airborne pollutants resulting from industrial processes, residential heating, and motor vehicle exhausts (Pershagen 1990) . Air pollution might also contribute to increased cancer risk in humans (Hemminki and Pershagen 1994) . The incomplete combustion of organic matter in the environment results in the release of a complex mixture of airborne pyrolysis products, including polycyclic aromatic hydrocarbons (PAHs).
PAHs constitute one of the major classes of airborne carcinogens (IARC 1993) and can be metabolized to DNA binding derivatives that form DNA adducts (Pershagen 1990) . Studies have shown that the main contributors to genotoxicity are PAHs and their derivatives (Binkova et al. 1999; Cerna et al. 1999; Hsiao et al. 2000) . Recently, it has been demonstrated that reduction of exposure to particulate air pollution lowers the risk of heritable mutations in mice suggesting health risks for future generations (Samet et al. 2004; Somers et al. 2004 ).
Chemical analysis of complex mixtures in ambient air is difficult since many chemically diverse and biologically active components occur at low concentrations. The National Institute of Standards and Technology (NIST) have developed a number of natural matrix standard reference materials (SRMs) since the early 1980s for the determination of organic contaminants in environmental matrices (Wise SA 1997) . The first particle-based, environmental natural matrix SRM developed by NIST for organic contaminants was SRM 1649 (Urban dust/Organics) (May 1984; Wise SA 2000) . SRM 1649a is the same particulate material that was issued previously in 1982 as SRM 1649 (National Institute of Standards and Technology 1982) ; it contains 44 or more PAHs, many polychlorbiphenyl (PCB) congeners, chlorinated pesticides and inorganic constituents. In our studies, we used SRM 1649a in addition to representative examples of carcinogenic PAHs, benzo [a] pyrene (BP) and dibenzo [a,l] pyrene (DBP) to understand the metabolic activation and DNA binding of these PAHs within complex mixtures. Both BP and DBP have been demonstrated to form stable DNA adducts in MCF-7 cells in culture (Mauthe et al. 1995; Ralston et al. 1994) . It has been shown that PAHs accumulate in breast tissue (Larsen et al. 1998) and that exposure to PAHs may lead to increased risk of breast cancer (Brody and Rudel 2003; Jeffy et al. 2002) . In a recent study, the expression of CYP1A1 and CYP1B1 genes was increased in MCF-7 cells, 24 h after treatment with BP alone or co-treatment with SRM 1649a (Mahadevan et al. 2005a ). In the current work we studied the long term effects of the complex environmental mixture SRM 1649a on the metabolic activation of BP and DBP by CYP1A1 and CYP1B1, and PAH-DNA adduct formation in MCF-7 cells in culture. (Schubert et al. 2003) have recently determined the presence of DBP (47.2 µg/kg) in SRM 1649a.
Cell culture and treatment
The MCF-7 cells (obtained from the Karmanos Cancer Center, Detroit, MI) were cultured in a 75 The concentrations of BP and DBP used in this study were based on previous studies in our laboratory which indicated that these doses gave detectable levels of DNA binding without causing excessive toxicity to the cell (Mahadevan et al. 2005b ). We used a dose of BP that was 100-fold higher in concentration than DBP based on their relative carcinogenic potency in mouse skin assay (Marston et al. 2001) . Determination of cytotoxicity for 120 h by MTT cell proliferation assay indicated that co-treatment of SRM 1649a and BP or DBP was more toxic to MCF-7 cells compared to SRM 1649a and DBP alone (data not shown). Also, treatment with SRM 1649a alone was toxic to cells.
DNA isolation
A standard DNA isolation protocol was used (Luch et al. 1998) . Briefly, cell pellets from two T-75 flasks per treatment group were pooled and homogenized in cell lysis buffer [10 mM Tris, 1 mM Na 2 EDTA, 1% SDS, pH 8]. The homogenates were treated with RNase, DNase-free (50 U/ml) and RNase T1 (1000 U/ml) at 37°C for 1 h, followed by treatment with proteinase K (500 µg/ml) at 37°C for 1 h. The DNA was extracted in light phase gel lock tubes with equal volumes of Tris-equilibrated phenol followed by extraction with 1:1 volume of Tris-equilibrated phenol 
P-Postlabeling of DNA Adducts and HPLC
Post-labeling was carried out as described previously (Ralston et al. 1995) . Briefly, 10 µg DNA isolated from MCF-7 cells after treatment were digested with nuclease P1 ( (Lau and Baird 1991) . Three independent sets of the postlabeling reactions were carried out for every sample treated, to determine the total PAH-DNA adduct levels.
Microsome isolation
Microsomes were prepared as described previously (Otto et al. 1991) with minor modifications. 
Ethoxyresorufin O-Deethylation (EROD) assay
Fifty micrograms of microsomal protein were added to 1 µM 7-ethoxyresorufin (ERES) (Sigma) in 200 µl of 0.1 M Tris HCl (pH 7.8) buffer per well in black 96-well plate (E&K Scientific, Campbell, CA). NADPH (Sigma) was added to each well and the fluorescence was measured in a Spectra MAX Gemini plate reader (Molecular Devices, Sunnyvale, CA). The excitation and emission wavelength were 535 nm and 585 nm respectively and the kinetic assay was monitored over 10 min. The experiment was repeated three times and each sample was assayed in triplicates. The amount of resorufin produced was calculated from the fluorescence of a known concentration of resorufin.
Western blots
Microsomal proteins (50 µg) were denatured by boiling for 3 min and separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis on 8 % acrylamide gels (Sigma). After (1:1500) (Sigma) followed by anti-mouse HRP conjugated secondary antibody (1:20,000).
Microsomal proteins (10 µg) from chinese hamster ovary V79 cells expressing either human CYP1A1 or CYP1B1 were used as positive controls.
Statistical Analysis
DNA Adduct data were averaged over one to three replicate reactions and the means were log transformed for analysis due to residuals on the original scale either having right skew or The HPLC profile of BP-DNA adducts revealed one major peak eluting at a retention time of 19 min (Fig. 1A,B panel 1 ). This major peak corresponded with the (+)-anti-BPDE-dG adduct peak of BP and was the significant adduct resolved in the SRM 1649a and BP cotreatment (Fig. 1A,B panel 2) . A reduction in the peak area was observed over time in cotreatment of SRM 1649a and BP in comparison to BP alone (Fig. 1A ,B, panel 1 and 2). MCF-7 cells treated with DBP exhibited four major DBPDE-DNA adducts with retention times of 50, 55, 57, and 62 min ( Fig. 2A) . Over time a reduction in the peak area was observed in cotreatment of SRM 1649a and DBP ( Fig. 2A,B panel 1 and 2 ).
Reduction in total DNA binding on co-treatment with SRM 1649a and carcinogenic PAH over time
The level of PAH-DNA adducts formed in MCF-7 cells treated with BP, or in co-treatment with SRM 1649a are graphically represented in Figure 3A . The highest level of DNA binding was observed in cells treated with BP (79.2 pmol/mg of DNA) after 48h of exposure (Fig. 3A) . The mean adduct levels for the BP treatment group was higher in comparison to co-treatment with SRM 1649a. When averaged over time, a significant decrease (p<0.01) was observed in the total BP-DNA adducts formed in co-treatment with SRM 1649a and BP. Analysis of log transformed data of DNA adducts revealed that co-treatment with SRM 1649a and BP was 2.8 fold less than BP alone. The maximum decrease in the level of DNA binding when co-treated with SRM 1649a and BP was identified at 120h (3.6 pmol/mg of DNA) in comparison to BP alone (8.66
pmol/mg of DNA), although it was not significant (p=0.36) (Fig. 3A) .
The level of PAH-DNA adducts formed in MCF-7 cells treated with DBP and cotreatment with SRM 1649a are graphically represented in Figure 3B . The level of DNA adducts formed when treated with DBP alone was relatively stable from 48 to 120h, with the highest level of DNA binding (34.2 pmol/mg) after 72h of exposure (Fig. 3B) . On co-treatment with SRM 1649a and DBP there was 18.7 fold less DBP-DNA adducts than with DBP alone.
Therefore, a very significant decrease (p<0.0001) in the total DBP-DNA adducts was observed over time in co-treatment with SRM 1649a and DBP (Fig. 3B) . The maximum decrease in the level of DNA binding was identified at 120h where the total DNA adducts in cells treated with DBP alone was 19.5 pmol/mg of DNA in comparison to 0.3 pmol/mg of DNA on co-treatment with SRM 1649a plus DBP (Fig. 3B ). The effect of SRM 1649a in co-treatments with carcinogenic PAH on CYP enzyme activity as measured by EROD assay is illustrated in Figure 4 . A significant difference (p<0.05) in CYP enzyme activity between treatment groups was evident over time. BP alone and co-treatment of SRM 1649a plus BP exhibited the highest EROD activity levels over time. Treatment groups SRM 1649a alone and SRM 1649a plus DBP indicated very low but similar EROD activity levels over time (Fig. 4) . DBP alone and DMSO exhibited the lowest level of EROD activity in comparison to other treatment groups analyzed over time.
Cytochrome P450 enzyme activity and induction
Western analyses were performed to examine the effect of SRM 1649a alone and in cotreatments with BP or DBP on CYP1A1 and CYP1B1 in MCF-7 cells 24, 48 and 120h after exposure (Fig. 5) . Treatment with DMSO, DBP or SRM 1649a alone did not induce CYP1A1
protein in the exposure times studied. However, basal levels of CYP1B1 were observed with DMSO, DBP and SRM 1649a treatment groups after 24, and/or 48h after exposure (Fig. 5A , 5B, 5A,B). An additive increase in the expression of CYP1A1 and CYP1B1 was observed with cotreatments of SRM 1649a and BP in comparison to BP alone (Fig. 5A,B) , while in 1649a cotreatment with DBP only at 48 h, basal levels of CYP1B1 protein were observed (Fig. 5A,B) .
However, treatment with DBP alone revealed no induction of CYP1B1 except at 48h. At 120h CYP1A1 induction was observed in BP and co-treatment with SRM 1649a, while CYP 1B1 protein was detected in treatment groups BP, BP plus SRM 1649a and DBP plus SRM 1649a (Fig. 5C ).
DISCUSSION
Environmental pollutants from coal tar, diesel exhaust, and urban dust are known to cause DNA damage. The carcinogens present in complex mixtures of environmental pollutants can be metabolized by CYP enzymes producing metabolites that bind to DNA. Recently, in vitro and in vivo experiments have demonstrated the formation of DNA adducts after exposure to a complex mixture containing PAH from coal tar (Cizmas et al. 2004; Mahadevan et al. 2005a; Mahadevan et al. 2005b; Marston et al. 2001) , diesel exhaust particulate (Kuljukka-Rabb et al. 2001; Lazarova and Slamenova 2004; Pohjola et al. 2003; Reliene et al. 2005 ) and urban dust (Mahadevan et al. 2005a) . In an occupational cohort study by Peluso et al. (Peluso et al. 2001) where they examined the relationship between air pollution exposure and DNA adducts, the authors conclude that the association was significant for both heavily exposed industrial workers and less severely exposed urban workers. Also, DNA adduct levels in exposed workers were significantly correlated with levels of BP in the air (Peluso et al. 2001) . In order to understand the possible link to breast cancer and long term effects potentially attributable to exposure to urban dust, we studied the effects of SRM 1649a on MCF-7 cells in culture up to 120h. An epidemiological study on the short-term exposure (24h) to SRM 1649a indicated increased nasal secretion levels of interleukins (Riechelmann et al. 2004 ) supporting the observations that shortterm increase of outdoor particulate matter concentration increases the frequency of upper respiratory diseases (Riechelmann et al. 2004) . Recently, it was also demonstrated that short term exposure (24h) of MCF-7 cells to SRM 1649a altered gene expression patterns (Mahadevan et al. 2005a ).
Here we discuss the first study involving an extended length of exposure (120h) to SRM 1649a in vitro to determine if the components of SRM 1649a were competing with the metabolic activation of the carcinogenic PAH in co-treatment with BP or DBP. The level of BP-DNA adducts significantly decreased over time in the presence of SRM 1649a (Fig. 3A) . SRM 1649a very significantly decreased the level of DBP-DNA adducts formed over time. This reduction was evident at each time point and was more pronounced at 96 and 120h of exposure (Fig. 3B) .
A similar phenomenon was reported by Binkova and Sram (Binkova and Sram 2004) in human diploid lung fibroblasts where BP-DNA adduct levels were up to 5-fold lower in an artificial carcinogenic PAH mixture and up to 10-fold lower in an environmental mixture. In our study, it
was not clear if the decrease occurred due to treatment toxicity, or removal of DNA adducts by DNA repair and replication. It is possible that the DNA adduct levels reached a saturation point after exposure to the complex mixture and carcinogenic PAH. As reported in a study by (Peluso et al. 2001) , the relation between DNA adducts and BP in peripheral blood cells was linear at low doses and sublinear at high doses indicating that DNA adduct formation tends to reach a saturation point at higher levels of exposure to chemical mixtures (Peluso et al. 2001) . Further experiments need to be conducted with varying levels of exposure to the urban dust mixture and carcinogenic PAH to test if this may have occurred with co-treatments of SRM 1649a and BP or DBP.
Previous studies on SRM 1649a (Mahadevan et al. 2004; Mahadevan et al. 2005a ) as well as this study suggest that there may be a selective metabolism of certain PAH within complex mixtures, which may be influenced by different CYP enzymes. We hypothesized that the components within SRM 1649a may be affecting the metabolism of BP and DBP by CYP enzymes. Higher EROD activity levels corresponded with protein induction of CYP enzymes as analyzed by Western blots in SRM 1649a co-treatment with BP ( Fig.4 and 5A,B) . However, cotreatment with SRM 1649a and DBP did not reveal a clear correlation with regard to EROD activity and CYP1A1 or CYP1B1 induction levels. These results suggest that the two CYP enzymes may have different roles in the metabolic activation of certain carcinogenic PAHs found in environmental mixtures (Diamond and Baird 1977; Shimada and Fujii-Kuriyama 2004) .
The difference in CYP1A1 enzyme activity and protein induction levels observed in cotreatments with SRM 1649a and BP or DBP could also be due to DBP being a poor inducer of CYP1A1 dependent proteins and enzyme activity, as the CYP1A1 induction levels observed were in accordance with induction equivalency factors reported for DBP ((Machala et al. 2001) .
The decrease in PAH-DNA adduct levels in co-treatment with SRM 1649a (Fig. 3 ) was similar to a study with complex mixture derived from coal tar (Mahadevan et al. 2005b ). This decrease implies that an inhibitory effect of SRM 1649a on CYP enzymes may have resulted in the decreased metabolism of the carcinogenic PAH. Future biochemical experiments are planned with SRM 1649a to elucidate the mechanism of inhibition of CYP enzymes. On the other hand, although there was no decrease in the EROD activity in the BP and SRM 1649a cotreatment (Fig. 4) a decrease in the DNA adducts levels in comparison to BP were observed (Fig.   3A ). There is a possibility that this decrease in DNA adduct levels may be due to detoxification of BP metabolites that form DNA adducts by the induced CYP1A1 as discussed in the in vivo studies by Uno et al (Uno et al. 2004 ). Another possible mechanism by which the components of SRM 1649a could affect the DNA is through the formation of quinones (for example BP-7,8-dione) that could cause oxidative damage to the DNA as described by Harvey et al (Harvey et al. 2004 ). 
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